Suzanne Tompkins, PA
Medical · Centreville, ALNPI 1871965236
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 340 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,519 and has fallen 59.5% since, to $615 in 2025.
Across 340 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$768
- Novo Nordisk$645
- Bayer$465
- AstraZeneca$390
- Amgen$340
- GSK$317
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,28698%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 60 | $768 |
| Novo Nordisk | 40 | $645 |
| Bayer | 30 | $465 |
| AstraZeneca | 25 | $390 |
| Amgen(2 entities) | 23 | $340 |
| GSK | 16 | $317 |
| AbbVie | 19 | $303 |
| Corium, LLC | 12 | $281 |
| Otsuka America Pharmaceutical, Inc. | 11 | $206 |
| Novartis | 12 | $203 |
| Merck | 14 | $182 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $175 |
| Pfizer | 18 | $146 |
| Neurocrine Biosciences, Inc. | 5 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $116 |
| Astellas Pharma US Inc | 1 | $100 |
| Abbott | 4 | $67 |
| Tris Pharma Inc | 4 | $57 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Dexcom, Inc. | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Exact Sciences | 2 | $34 |
| Optinose US, Inc. | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Boehringer Ingelheim | 2 | $25 |
| Genentech USA, Inc. | 2 | $22 |
| Ossur Americas, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Philips North America LLC | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Eisai Inc. | 1 | $13 |
How this compares
$5,386 in reported general payments places this provider in the 85th percentile of 175 medical providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 151 | $180,512 |
| JardianceEmpagliflozin | 132 | $166,203 |
| OzempicSemaglutide | 127 | $129,924 |
| EliquisApixaban | 100 | $109,116 |
| FarxigaDapagliflozin Propanediol | 41 | $38,080 |
| XareltoRivaroxaban | 30 | $34,823 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $34,200 |
| RexultiBrexpiprazole | 22 | $32,043 |
| TrulicityDulaglutide | 23 | $31,001 |
| JanuviaSitagliptin Phosphate | 27 | $26,005 |
| MyrbetriqMirabegron | 28 | $23,784 |
| Colesevelam Hcl | 23 | $12,185 |
| EntrestoSacubitril/Valsartan | 11 | $9,859 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 86 | $9,451 |
| Repatha SureclickEvolocumab | 15 | $8,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $768 | $211,512174 claims |
| Boehringer IngelheimJardiance | $25 | $166,203132 claims |
| Novo NordiskOzempic | $645 | $129,924127 claims |
| PfizerEliquis | $146 | $109,116100 claims |
| AstraZenecaFarxiga | $390 | $38,08041 claims |
| Johnson & JohnsonXarelto | $14 | $34,82330 claims |
| GSKTrelegy Ellipta | $317 | $34,20045 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $206 | $32,04322 claims |
| MerckJanuvia | $182 | $26,00527 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $23,78428 claims |
| NovartisEntresto | $203 | $9,85911 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $14 | $7,81413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 175 medical providers in Alabama.
Other medical in Centreville
- Lindsey MangumFlorence$44K
- Jaime DunnBirmingham$16K
- Stacy RichersonMobile$12K
- Susannah CashAuburn$11K
- Deana PorterAuburn$9K
- Rachel ThompsonFairhope$9K
- Shelley WinzelerHomewood$8K
- Reiga EvansHuntsville$8K
- Lillian ShafferCullman$8K
- Lauren TidwellHuntsville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.